People with pulmonary hypertension (PH) who were diagnosed with COVID-19 had a high rate of hospitalization and in-hospital mortality,…
Articles by Steve Bryson, PhD
Sacubitril/valsartan, a fixed-dose combination oral therapy approved for heart failure, was found to improve right heart function and lower pulmonary…
Switching from Tracleer (bosentan) to Opsumit (macitentan) improved physical abilities with fewer side effects in some adults with…
The International Society for Heart and Lung Transplantation (ISHLT) has launched the ISHLT Foundation, a new organization that…
Maximum oxygen uptake measured during cardiopulmonary exercise testing (CPET) independently predicted long-term survival outcomes in people with pulmonary hypertension…
Tyvaso DPI, an investigational dry powder formulation of the vasodilator treprostinil, was equally safe and effective, and more convenient than…
Newly revealed biological mechanisms that underlie the development of pulmonary arterial hypertension (PAH) support activating BMPR2, the protein mutated…
Supplemental long-term oxygen therapy is the only effective treatment for people with pulmonary hypertension (PH) associated with chronic obstructive…
Breathing reserve, a measure of lung function calculated during exercise, predicted survival in adults with congenital heart disease associated with…
A passive leg raise is equally as effective as exercise in measuring pulmonary vascular distensibility, a physiological marker to predict…
Gene activity analysis of whole blood collected from people with pulmonary arterial hypertension (PAH) identified three patient subgroups associated…
PhaseBio Pharmaceuticals has voluntarily ended the Phase 2b trial testing its investigational pulmonary arterial hypertension (PAH) therapy pemziviptadil…